Teligene
Latest round
- Series C
Last raised
- Aug 2018
Total raised
- Undisclosed
Investors
- 10
About Teligene
Based in Suzhou, China and established in 2011, SuZhou Teligene, Ltd. is a biotechnology company that develops small molecule new drugs for cancer treatment. The company was founded by Amgen's chief scientist, Dawei Zhang., Ltd. The company is committed to developing anti-tumour therapeutics with its own intellectual property rights. Its product line covers several pipeline projects, with major products such as EGFR small molecule inhibitors Sutentinib, TL118 and Cernetinib. The company generates revenue by providing anti-tumour therapeutic drugs such as Sutentinib.
Who invested in Teligene
10 investors across 2 rounds
See all investors in Teligene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Teligene
Who invested in Teligene?
Teligene has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Teligene raised?
Teligene has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Teligene last raise money?
Teligene's most recent round on record is a Series C, in Aug 2018.
What does Teligene do?
Based in Suzhou, China and established in 2011, SuZhou Teligene, Ltd.
Where is Teligene headquartered?
Teligene is headquartered in Suzhou, China.
Which VCs invest in companies like Teligene?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Teligene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Teligene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.